RE:Boy am I glad I was out! but at $11 and change???On the surface the company looks like a value play. My main concern is Donnatal. It has yet to prove to the FDA it is effective. 18,400 DESI drugs have proven they are effective. Donnatal is 2 of only 12 that has yet to prove it is effective. Sooner or later the FDA will get tired of waiting for evidence and just proceed. Has anybody asked the company about this?
FullReversal wrote:
I've been buying and selling this this over longer cycles and doing well. At below $12.... the other shoe can fall here with banksters' downgrades or take over suitors can be tripping over each other for a chance to take this on.
Problem is, if they want to take it private, they can continue to pound away at it at shareholder's expense. I actually hate the sector, drug price gouging isn't what makes me a proud member of the true investor community. Brand names are under assault from the generics and that's supported by the politicians and public.
That and the Amdipharm Mercury acquisition stinks to high heaven, that's the biggest obstacle I see to me putting my money back on this horse! But from a pure financial perspective, sub $12 looks mighty good.... Anyone have any better picks for the contrarians?
Or maybe I'll just wait this out a bit more.... Let's see if there is any intelligence responses... Something very, very hard to get from Stockhouse...